Back to search
Advanced Solid Tumors With KRAS G12C Mutations
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced Solid Tumors With KRAS G12C Mutations trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced Solid Tumors With KRAS G12C Mutations trials you may qualify forThis study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KR…
The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The m…
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This stu…
Researchers are looking for a better way to treat people who have advanced solid cancers with a KRASG12C mutation. Sotorasib is a drug that targets cancer cell…
Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Research…
The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-can…
To evaluate safety, tolerability, PK, and preliminary efficacy of AMG 510 PO QD in subjects of Chinese descent with KRAS p.G12C-mutant advanced/metastatic solid…
The goal of this study is to learn if KQB368 works to treat advanced solid malignancies in adults. The study will also learn about the safety of KQB368. The mai…
This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G…